FBRX News and Press, Forte Biosciences Inc. From 08/17/21

LM Funding America LMFA +24% on Q2 earnings. Forte Biosciences (NASDAQ:FBRX) +17%. Powerbridge Technologies PBTS +14% on signing pact with Cryptodigital to acquire bitcoin and ethereum miners Danimer Scientific DNMR +13% on Q2 earnings. Helius Medical Technologie...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re starting off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday. Source: f11photo/Shutterstock.com But before that, take a moment to look over som...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline d...

Forte Biosciences (FBRX) has filed for a mixed shelf offering of up to $300M.The filing does not necessarily indicate that a sale has begun, or will occur in the future.Forte shares are down 0.7% to $35.31 in after-hours trading. For further details see: Forte Biosciences file...

Forte Biosciences ([[FBRX]] +1.4%) anticipates topline results in Q3 2021 from a Phase 2 trial for its lead asset FB-401 in atopic dermatitis ((AD)) for patients aged 2 years and older.Citi analysts Mohit Bansal and James Shin consider the readout as a major catalyst that could propel th...

Fate's early stage data look promising: JefferiesFate Therapeutics (FATE) shares shed ~1.4% after the company announced data from an early stage leukemia trial for its natural killer ((NK)) cell programs.Fate has lost ~21.3% in the year so far and noting that data looked promising and have de...

Forte Biosciences, Inc. (FBRX) Q1 2021 Earnings Conference Call May 10, 2021, 04:30 PM ET Company Participants Paul Wagner - CEO Dan Birch - CMO Tony Riley - CFO Conference Call Participants Mohit Bansal - Citigroup Kumar Raja - Brookline Capital Markets Michael Higgins - Ladenburg Thalmann K...

Forte Biosciences (FBRX): Q1 GAAP EPS of -$0.36 beats by $0.17.Cash and cash equivalents of $54.8MPress Release For further details see: Forte Biosciences EPS beats by $0.17

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces first quarter 2021 results and provides a general business update on May 10, 2021. “Forte has continued to make excellent progress in the fist quarter of 20...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general business update on May 10, 2021. Conference Call and Webcast Information Forte management will host a con...